[{"id":"eb62f63b-46a3-403c-9502-f4a772f2f94b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06934590","created_at":"2025-09-07T01:19:25.316Z","updated_at":"2025-09-07T01:19:25.316Z","phase":"Phase 1","brief_title":"Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC","source_id_and_acronym":"NCT06934590","lead_sponsor":"GeneCraft Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-04-23"},{"id":"9de3eb66-06bd-4d1a-92a9-adae61b8b59a","acronym":"Acclaim-1","url":"https://clinicaltrials.gov/study/NCT04486833","created_at":"2021-01-18T21:32:20.912Z","updated_at":"2025-02-25T12:27:38.683Z","phase":"Phase 1/2","brief_title":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","source_id_and_acronym":"NCT04486833 - Acclaim-1","lead_sponsor":"Genprex, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • Reqorsa (quaratusugene ozeplasmid)"],"overall_status":"Recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 09/03/2021","start_date":" 09/03/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-02-24"},{"id":"8219a865-ee1b-4147-b478-9542d52eab59","acronym":"","url":"https://clinicaltrials.gov/study/NCT02858310","created_at":"2021-01-18T14:01:47.880Z","updated_at":"2024-07-02T16:34:58.731Z","phase":"Phase 1/2","brief_title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","source_id_and_acronym":"NCT02858310","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 01/27/2017","start_date":" 01/27/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-06-05"},{"id":"937bec61-abb0-4838-bc7e-ee7138f0f459","acronym":"MED20-165","url":"https://clinicaltrials.gov/study/NCT04512716","created_at":"2021-01-18T21:37:46.095Z","updated_at":"2024-07-02T16:35:15.633Z","phase":"Phase 1","brief_title":"Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04512716 - MED20-165","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT) • vadacabtagene leraleucel (JCAR015)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-08"},{"id":"962576ef-c5c5-4f0a-80e9-6c715c5905d8","acronym":"GENHIV","url":"https://clinicaltrials.gov/study/NCT03593187","created_at":"2021-01-18T17:40:09.381Z","updated_at":"2024-07-02T16:36:00.861Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma","source_id_and_acronym":"NCT03593187 - GENHIV","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" CD8 • CD34 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD34 • CD4"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 01/15/2019","start_date":" 01/15/2019","primary_txt":" Primary completion: 07/28/2020","primary_completion_date":" 07/28/2020","study_txt":" Completion: 07/28/2020","study_completion_date":" 07/28/2020","last_update_posted":"2022-11-07"},{"id":"81299e80-d031-4a6e-a4ba-57495996a748","acronym":"","url":"https://clinicaltrials.gov/study/NCT04044950","created_at":"2021-06-30T14:53:45.767Z","updated_at":"2024-07-02T16:36:40.811Z","phase":"Phase 2","brief_title":"A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer","source_id_and_acronym":"NCT04044950","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7 TCR cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/29/2019","start_date":" 07/29/2019","primary_txt":" Primary completion: 09/17/2020","primary_completion_date":" 09/17/2020","study_txt":" Completion: 09/17/2020","study_completion_date":" 09/17/2020","last_update_posted":"2020-09-22"},{"id":"64b32301-3f36-4fa1-99fc-4f512b0b9e43","acronym":"","url":"https://clinicaltrials.gov/study/NCT00826150","created_at":"2021-01-18T03:08:32.308Z","updated_at":"2024-07-02T16:36:58.906Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer","source_id_and_acronym":"NCT00826150","lead_sponsor":"Anchiano Therapeutics Israel Ltd.","biomarkers":" H19","pipe":"","alterations":" ","tags":["H19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e inodiftagene vixteplasmid (BC 819)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 02/01/2012","study_completion_date":" 02/01/2012","last_update_posted":"2019-06-13"},{"id":"c1dc8724-8c28-46dc-84a4-74bea6e56812","acronym":"","url":"https://clinicaltrials.gov/study/NCT00595088","created_at":"2021-01-18T02:12:12.208Z","updated_at":"2024-07-02T16:37:00.046Z","phase":"Phase 2b","brief_title":"Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer","source_id_and_acronym":"NCT00595088","lead_sponsor":"Anchiano Therapeutics Israel Ltd.","biomarkers":" H19","pipe":"","alterations":" ","tags":["H19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e inodiftagene vixteplasmid (BC 819)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 01/01/2013","study_completion_date":" 01/01/2013","last_update_posted":"2019-04-30"},{"id":"3f865f0a-83d2-44a9-9a7e-64c608194e5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00711997","created_at":"2021-01-18T02:39:51.495Z","updated_at":"2024-07-02T16:37:01.512Z","phase":"Phase 1/2","brief_title":"Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT00711997","lead_sponsor":"Anchiano Therapeutics Israel Ltd.","biomarkers":" H19","pipe":"","alterations":" ","tags":["H19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e inodiftagene vixteplasmid (BC 819)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2019-03-20"},{"id":"11fe933c-a4d6-496a-a112-e60b2e4b87c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03313596","created_at":"2021-01-18T16:21:54.363Z","updated_at":"2024-07-02T16:37:03.209Z","phase":"Phase 3","brief_title":"Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC","source_id_and_acronym":"NCT03313596","lead_sponsor":"Huazhong University of Science and Technology","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ProstAtak (aglatimagene besadenovec)"],"overall_status":"Unknown status","enrollment":" Enrollment 180","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-02-04"},{"id":"8ed56c03-b80e-47ea-9f7b-2adb0e127840","acronym":"","url":"https://clinicaltrials.gov/study/NCT02378922","created_at":"2021-01-18T11:19:56.395Z","updated_at":"2024-07-02T16:37:04.358Z","phase":"Phase 1","brief_title":"Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma","source_id_and_acronym":"NCT02378922","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD34 • CD4","pipe":"","alterations":" ","tags":["CD34 • CD4"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 06/15/2019","primary_completion_date":" 06/15/2019","study_txt":" Completion: 06/15/2019","study_completion_date":" 06/15/2019","last_update_posted":"2018-12-27"}]